treatment for carotid bifurcation disease may be unfounded or even questioned has surprised vascular surgeons and put some in an uneasy and controversial position. It would seem that vascular surgeons have been happily floating on a cloud supported by worldwide acceptance of ostensibly excellent CEA results, only to have the cloud dissipate and send them plummeting back to earth.
The efficacy of CEA in the prevention of brain embolization from carotid bifurcation plaques is without doubt, but the appearance of endovascular carotid artery therapy has spawned a series of issues (not always does bad come from worse). Basically, these are the need to reaffirm the safety and efficacy of CEA on the one hand and, on the other, to definitively recognize carotid stenting as a valid alternative-or even the gold standard-for the treatment of the carotid bifurcation lesion. 4 The answer to this unhappy situation will very likely come from the randomized trials that have commenced or are about to start. 5, 6 It is interesting to note that in most, if not all, of these trials the indication for patient inclusion in either arm of the study is classically based on the presence or absence of symptoms and the percentage of carotid stenosis. 7 It should be remembered that as more recent data has indicated, 8, 9 CEA can be beneficial in symptomatic and asymptomatic patients with carotid stenoses between 60% and 99%. However, if diagnostic variables of plaque morphology are not employed, then a EDITORIAL BIASI J ENDOVASC THER 2001;8:339-340 large percentage of the population would be potential candidates for treatment of a carotid plaque. Consider the estimates that some 6% of the US population has a carotid bifurcation plaque and 10% of people 60 years and older have a Ͼ50% stenotic plaque. 10 According to these figures, the number of symptomatic subjects with an internal carotid stenosis between 60% and 99% who could potentially benefit from a procedure annually is 360 per 1,000,000 people; the number would become 522 per 1 million per year if asymptomatic subjects were also included. Thus, a total of over 130,000 carotid procedures would be required per year in the US.
These considerations should bring us to the conclusion that the criteria for a carotid procedure, which in daily practice are almost exclusively related to neurological symptoms and the percent stenosis, are insufficient and obsolete. It is therefore surprising that in the majority-and perhaps all-of the randomized or prospective ongoing studies on carotid artery stenting versus CEA, the criteria for classifying patients as high or low risk for treatment do not adequately consider the features and morphology of the carotid plaque. 11 Still, there is evidence that echolucent plaques produce more embolic particles than the echogenic ones, 12 and patients with echolucent plaques should be deemed at higher risk for brain embolization. Moreover, when an embolic protection device is used in conjunction with carotid stenting, protection throughout the periprocedural period cannot be guaranteed, and a certain percentage of neurological complications may be related to the protection device itself. Therefore, it may be that more careful attention should be directed to the morphology of the plaque when selecting a carotid stenting or CEA procedure. 13, 14 Subgroups of patients could be identified in whom plaque morphology would indicate that the risk of using a protection device is greater than that related to the plaque itself.
It would appear that the introduction of carotid stenting has not only produced a new scenario in the treatment of the carotid bifurcation stenosis, but it has also raised many questions that need to be definitely answered.
